Novartis Announces Positive 144-Week Data from ASC4FIRST Trial of Scemblix in Newly Diagnosed CML

Novartis' Scemblix Shows Superior Efficacy, Favorable Safety at 144 Weeks in CML

Novartis announced positive 144-week data from the pivotal ASC4FIRST trial of Scemblix (asciminib) at the 2026 ASCO Annual Meeting. The results demonstrated increasingly superior molecular responses at week 144 for Scemblix compared to standard-of-care (SoC) TKIs, including imatinib and second-generation (2G) TKIs, in adult patients with newly diagnosed Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase (Ph+ CML-CP). Scemblix achieved a 77.1% major molecular response (MMR) rate versus 53.4% for SoC TKIs, 79.2% versus 47.1% for imatinib, and 75.0% versus 59.8% for 2G TKIs. The drug also maintained a favorable safety and tolerability profile, with fewer grade ≥3 adverse events and lower discontinuation rates due to AEs compared to comparators.

• Sustained Superior Efficacy in Molecular Response: At week 144, Scemblix continued to show significantly higher major molecular response (MMR) rates compared to standard-of-care (SoC) TKIs. The MMR rate for Scemblix was 77.1% versus 53.4% for SoC TKIs overall, with a 15.2% higher MMR rate specifically against 2G TKIs (75.0% vs. 59.8%; P=0.01*). This progressive widening of the response difference over time reinforces Scemblix's sustained efficacy in achieving and maintaining molecular responses in newly diagnosed Ph+ CML-CP patients.
• Achievement of Deeper Molecular Responses and Improved Adherence: Scemblix not only delivered superior MMR rates but also led to deeper molecular responses, with higher percentages of patients achieving MR4 (55.7% vs. 36.3% for SoC) and MR4.5 (42.3% vs. 24.5% for SoC) at week 144. Furthermore, a significantly higher proportion of patients remained on Scemblix treatment compared to SoC TKIs (78.6% vs. 55.9%), imatinib (81.2% vs. 50.0%), and 2G TKIs (76.0% vs. 61.8%), indicating better long-term treatment adherence crucial for managing a chronic condition like CML.
• Favorable and Consistent Safety and Tolerability Profile: The 144-week data confirmed Scemblix's safety profile, consistent with previous findings and showing no new safety concerns. Compared to both imatinib and 2G TKIs, Scemblix demonstrated fewer grade ≥3 adverse events (49% vs. 52% and 63% respectively), fewer dose adjustments due to AEs (37% vs. 44% and 63%), and more than 50% lower discontinuation rates due to AEs (6% vs. 13% and 14%). This favorable tolerability profile is a key advantage for long-term therapy in CML.

Addressing the Long-Term Treatment Challenges in Newly Diagnosed CML

Despite significant advances in tyrosine kinase inhibitor (TKI) therapy, several critical challenges persist in managing Philadelphia chromosome-positive chronic myeloid leukemia in chronic phase. These limitations span from treatment resistance mechanisms to real-world adherence issues and safety considerations that complicate optimal patient management.

• Treatment resistance remains a significant barrier, with mutations within the Abl kinase domain representing a major cause of resistance in 40-50% of cases, while approximately 40% of relapsed patients exhibit uncharacterized BCR-ABL1 kinase-independent resistance mechanisms

• Patient adherence to TKI therapy presents substantial real-world challenges, with studies showing adherence rates of only 54.95% based on validated assessment scales, despite physician assessments reporting 90.39% adherence, highlighting a critical gap in monitoring

• Drug-related problems are nearly universal among patients, with 97% of CML patients experiencing at least one drug-related problem, including adverse drug events (45.5%), treatment ineffectiveness (31.5%), and patient treatment concerns or dissatisfaction (23%)

• Advanced disease stages remain difficult to treat, as accelerated phase or blast crisis CML responds poorly to treatments that are highly effective in chronic phase, emphasizing the critical need to maintain patients in chronic phase

• Safety considerations complicate TKI selection, particularly treatment-emergent vascular and pulmonary adverse events associated with second- and later-generation TKIs, requiring careful patient-specific risk-benefit assessments

• Lack of comparative data hinders optimal treatment sequencing, as no prospective randomized comparative studies exist for second- and third-generation TKIs, leaving physicians without clear guidance for initial treatment selection or optimal TKI sequencing

• Specific mutations present therapeutic dead ends, particularly the T315I mutation which confers inherent resistance to all licensed tyrosine kinase inhibitors, leaving limited treatment options for affected patients

• Lifelong treatment requirements impact quality of life, as continuous TKI administration is necessary for optimal outcomes, though approximately 60% of patients treated with second-generation TKIs may achieve deep molecular response prerequisites for potential treatment-free remission trials

ASC4FIRST: Unpacking 144-Week Efficacy Data for Scemblix in ND CML

Key clinical trials for Ph+ CML-CP demonstrate evolving treatment paradigms from first-generation TKIs to novel mechanisms like STAMP inhibition. These studies employ rigorous phase 2/3 designs with standardized molecular and cytogenetic endpoints, establishing the evidence base for current treatment algorithms.

Scemblix's Favorable Safety and Tolerability for Sustained CML Treatment

Published safety and tolerability data consistently demonstrate that asciminib (Scemblix) maintains a favorable safety profile across its studied indications, with particular advantages in cardiovascular safety compared to other tyrosine kinase inhibitors. The most recent comprehensive analyses show that asciminib enables sustained treatment with manageable adverse events and low discontinuation rates.

• Meta-analysis of 691 patients showed combined adverse event rate of 79.2% for all grades and 39.5% for grade ≥3 adverse events, with thrombocytopenia being the most common adverse event at 22.5% across all grades

• Long-term safety data spanning up to 8.4 years (median 5.9 years) in 115 patients demonstrated that grade ≥3 adverse events occurred in 76.5% of patients, with treatment discontinuation due to adverse events in only 13.0% of patients

• Most first-ever adverse events, particularly hematologic events, presented within the first year with no new safety signals emerging over long-term follow-up, supporting sustained tolerability

• Superior cardiovascular safety profile compared to other TKIs, with no cardiovascular events or occlusive arterial disease reported in real-world studies and reduced vascular and pulmonary risks

• Real-world US study of 255 patients showed 95.0% remained on asciminib at 48 weeks after one prior TKI, demonstrating excellent tolerability in clinical practice

• Phase 3 trial data showed fewer grade ≥3 adverse events with asciminib (50.6%) versus bosutinib (60.5%), and significantly lower treatment discontinuation rates (5.8% vs 21.1%)

• Cross-toxicity analysis revealed statistically significant risk for thrombocytopenia, anemia, neutropenia, fatigue, vomiting, and pancreatitis, though overall toxicity profile remained more favorable than classical TKIs

• FAERS pharmacovigilance data identified 663 significant adverse event terms across 27 system organ categories, with median onset time of 52.5 days and specific off-label use risks including hepatotoxicity and pancreatitis

Asciminib's Long-Term Frontline Data Solidifies CML Paradigm Shift

The 144-week data from the ASC4FIRST trial represents a pivotal moment for asciminib, solidifying its potential to redefine the treatment landscape for newly diagnosed chronic myeloid leukemia in chronic phase (CML-CP). For years, tyrosine kinase inhibitors (TKIs) have transformed CML care, yet challenges persist, particularly concerning long-term tolerability and the ability to achieve deep, durable molecular responses necessary for treatment-free remission. While second-generation TKIs offer improved efficacy over imatinib, their associated toxicities can lead to treatment interruptions or discontinuations, impacting patient quality of life and overall outcomes.

Asciminib, with its unique Specifically Targeting the ABL Myristoyl Pocket (STAMP) mechanism, offers a distinct advantage. Unlike traditional ATP-competitive TKIs, its allosteric binding minimizes off-target effects, translating into a more favorable safety and tolerability profile. The sustained superior major molecular response rates observed over 144 weeks, coupled with fewer adverse events and lower discontinuation rates compared to standard-of-care TKIs, underscore its potential to offer both potent disease control and a better patient experience from the outset. This could lead to improved adherence, a critical factor for long-term success in CML.

Strategically, these results position asciminib as a formidable challenger to existing frontline therapies, potentially shifting treatment algorithms. However, the competitive landscape remains dynamic. While asciminib demonstrated superiority over investigator-selected TKIs and imatinib, the direct statistical comparison against individual second-generation TKIs was not a primary objective, and the difference was less pronounced. This suggests that manufacturers of established 2G TKIs will likely emphasize their own long-term data and specific safety profiles. Furthermore, while asciminib's safety profile is favorable, continuous monitoring for any long-term cardiovascular effects, a known class effect of TKIs, will be crucial. The potential for resistance, even with its novel mechanism, also remains a consideration, highlighting the ongoing need for personalized approaches based on mutation status. Ultimately, asciminib's long-term frontline data offers a compelling new option, balancing efficacy with tolerability, and advancing the goal of sustained deep molecular responses for CML patients.